388 related articles for article (PubMed ID: 34775774)
1. The divergent protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on clinical outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.
Xie Q; Tang S; Li Y
Ann Palliat Med; 2022 Apr; 11(4):1253-1263. PubMed ID: 34775774
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
Kurdi A; Abutheraa N; Akil L; Godman B
Pharmacol Res Perspect; 2020 Dec; 8(6):e00666. PubMed ID: 33084232
[TBL] [Abstract][Full Text] [Related]
3. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Mortality Among COVID-19 Patients: A Systematic Review and Meta-Analysis.
Kashour T; Bin Abdulhak AA; Tlayjeh H; Hassett LC; Noman A; Mohsen A; Al-Mallah MH; Tleyjeh IM
Am J Ther; 2023 Jul-Aug 01; 30(4):e336-e346. PubMed ID: 33201001
[TBL] [Abstract][Full Text] [Related]
5. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on in-hospital mortality among patients with COVID-19: a systematic review and meta-analysis.
Cai XJ; Tay JCK; Kui SL; Tin AS; Tan VH
Singapore Med J; 2021 Nov; 62(11):563-567. PubMed ID: 33256355
[TBL] [Abstract][Full Text] [Related]
6. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
[TBL] [Abstract][Full Text] [Related]
7. Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis.
Batty JA; Tang M; Hall M; Ferrari R; Strauss MH; Hall AS
Syst Rev; 2018 Aug; 7(1):131. PubMed ID: 30144828
[TBL] [Abstract][Full Text] [Related]
8. Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia.
Lee HY; Ahn J; Park J; Kang CK; Won SH; Kim DW; Park JH; Chung KH; Joh JS; Bang JH; Kang CH; Oh MD; Pyun WB; ;
Korean J Intern Med; 2021 May; 36(3):617-628. PubMed ID: 33858123
[TBL] [Abstract][Full Text] [Related]
9. Association of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers with risk of mortality, severity or SARS-CoV-2 test positivity in COVID-19 patients: meta-analysis.
Biswas M; Kali MSK
Sci Rep; 2021 Mar; 11(1):5012. PubMed ID: 33658619
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
[TBL] [Abstract][Full Text] [Related]
11. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Grover A; Oberoi M
Eur Heart J Cardiovasc Pharmacother; 2021 Mar; 7(2):148-157. PubMed ID: 32542337
[TBL] [Abstract][Full Text] [Related]
12. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis.
Pirola CJ; Sookoian S
J Infect; 2020 Aug; 81(2):276-281. PubMed ID: 32474043
[TBL] [Abstract][Full Text] [Related]
13. Effects of renin-angiotensin-aldosterone system inhibitors on disease severity and mortality in patients with COVID-19: A meta-analysis.
Zhang G; Wu Y; Xu R; Du X
J Med Virol; 2021 Apr; 93(4):2287-2300. PubMed ID: 33231299
[TBL] [Abstract][Full Text] [Related]
14. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.
Li J; Wang X; Chen J; Zhang H; Deng A
JAMA Cardiol; 2020 Jul; 5(7):825-830. PubMed ID: 32324209
[TBL] [Abstract][Full Text] [Related]
15. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
Mehta N; Kalra A; Nowacki AS; Anjewierden S; Han Z; Bhat P; Carmona-Rubio AE; Jacob M; Procop GW; Harrington S; Milinovich A; Svensson LG; Jehi L; Young JB; Chung MK
JAMA Cardiol; 2020 Sep; 5(9):1020-1026. PubMed ID: 32936273
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or Hospitalization With COVID-19 Disease: A Systematic Review and Meta-Analysis.
Tleyjeh IM; Bin Abdulhak AA; Tlayjeh H; Al-Mallah MH; Sohail MR; Hassett LC; Siller-Matula JM; Kashour T
Am J Ther; 2020 Dec; 29(1):e74-e84. PubMed ID: 33395057
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System.
An J; Wei R; Zhou H; Luong TQ; Gould MK; Mefford MT; Harrison TN; Creekmur B; Lee MS; Sim JJ; Brettler JW; Martin JP; Ong-Su AL; Reynolds K
J Am Heart Assoc; 2021 Feb; 10(3):e019669. PubMed ID: 33307964
[TBL] [Abstract][Full Text] [Related]
18. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 and the Angiotensin-Converting Enzyme 2 Receptor: Angiotensin-Converting Enzyme Inhibitor/Angiotensin 2 Receptor Blocker Utilization and a Shift Towards the Renin-Angiotensin-Aldosterone System Classical Pathway.
Felber R; New W; Riskin SI
Cureus; 2024 Mar; 16(3):e55563. PubMed ID: 38576704
[TBL] [Abstract][Full Text] [Related]
20. Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review.
Mackey K; King VJ; Gurley S; Kiefer M; Liederbauer E; Vela K; Sonnen P; Kansagara D
Ann Intern Med; 2020 Aug; 173(3):195-203. PubMed ID: 32422062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
